<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21</volume><submitter>Zheng W</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The presence of residual DNA carried by biological products in the body may lead to an increased oncogenicity, infectivity, and immunomodulatory risk. Therefore, current agencies including WHO, EU, and the FDA limited the accepted amounts of residual DNA (less than 10 ng or 100 pg/dose). Among the methods of detecting residual DNA, qPCR is considered to be the most practical for residual DNA quantitation due to its sensitivity, accuracy, precision, and time-saving.&lt;h4>Results&lt;/h4>In this study, the detection capacity of this method was determined by comparing the detected concentration of the commercial kit and the self-designed primer/probe set after the same treatment of the extraction method. Then, a universal sample pretreatment method based on a co-precipitant was o</pubmed_abstract><journal>Biological procedures online</journal><pagination>17</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6717637</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and Validation of Quantitative Real-Time PCR for the Detection of Residual CHO Host Cell DNA and Optimization of Sample Pretreatment Method in Biopharmaceutical Products.</pubmed_title><pmcid>PMC6717637</pmcid><pubmed_authors>Li G</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Jiang L</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Kong T</pubmed_authors><pubmed_authors>Gao X</pubmed_authors><pubmed_authors>Zheng W</pubmed_authors><pubmed_authors>Lei Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and Validation of Quantitative Real-Time PCR for the Detection of Residual CHO Host Cell DNA and Optimization of Sample Pretreatment Method in Biopharmaceutical Products.</name><description>&lt;h4>Background&lt;/h4>The presence of residual DNA carried by biological products in the body may lead to an increased oncogenicity, infectivity, and immunomodulatory risk. Therefore, current agencies including WHO, EU, and the FDA limited the accepted amounts of residual DNA (less than 10 ng or 100 pg/dose). Among the methods of detecting residual DNA, qPCR is considered to be the most practical for residual DNA quantitation due to its sensitivity, accuracy, precision, and time-saving.&lt;h4>Results&lt;/h4>In this study, the detection capacity of this method was determined by comparing the detected concentration of the commercial kit and the self-designed primer/probe set after the same treatment of the extraction method. Then, a universal sample pretreatment method based on a co-precipitant was o</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019</publication><modification>2025-04-22T06:13:15.635Z</modification><creation>2019-09-12T07:04:31Z</creation></dates><accession>S-EPMC6717637</accession><cross_references><pubmed>31496923</pubmed><doi>10.1186/s12575-019-0105-1</doi></cross_references></HashMap>